CD274 and neoplasm: Indeed, in the following KEYNOTE 361, IMvigor130 and Danube phase III randomised trials, the anti-PD1/PD-L1 agents either alone or in combination with chemotherapy were not superior to the chemotherapy according to OS in patients with high PD-L1 tumours, as well as in the overall population [50,51,52].